FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2891145791> ?p ?o ?g. }

• W2891145791 endingPage "238" @default.
• W2891145791 startingPage "227" @default.
• W2891145791 abstract "Non-alcoholic steatohepatitis (NASH) is the leading cause of cirrhosis worldwide and the most rapidly growing indication for liver transplantation. Macrophages are the important cellular component in the inflammatory milieu in NASH. Inflammatory and pro-fibrotic mediators produced by macrophages causes significant tissue injury in many inflammatory diseases. Therefore, inhibition of the inflammatory macrophages would be a promising approach to attenuate NASH. In this study, we studied the implication of SYK pathway in NASH, and investigated PLGA nanoparticles-based delivery of SYK pathway inhibitor as an effective and promising therapeutic approach for the treatment of NASH. We found positive correlation between SYK expression with the pathogenesis of NASH and alcoholic hepatitis in patients. Importantly, SYK expression was significantly induced in M1-differentiated inflammatory macrophages. To inhibit SYK pathway specifically, we used a small-molecule inhibitor R406 that blocks Fc-receptor signaling pathway and reduces immune complex-mediated inflammation. R406 dose-dependently inhibited nitric-oxide release and M1-specific markers in M1-differentiated macrophages. Thereafter, we synthesized PLGA nanoparticles to deliver R406 to increase the drug pharmacokinetics for the efficient treatment of NASH. We investigated the therapeutic efficacy of R406-PLGA in-vitro in differentiated macrophages, and in-vivo in Methionine-Choline-deficient (MCD)-diet induced NASH mouse model. R406-PLGA inhibited M1-specific differentiation markers in RAW and bone-marrow-derived macrophages. In-vivo, R406 and more strongly R406-PLGA ameliorated fibrosis, inflammation and steatosis in mice. R406 and more significantly R406-PLGA reduced ALT, AST, cholesterol and triglyceride plasma levels. These results suggest that delivery of SYK inhibitor using PLGA nanoparticles can be a potential therapeutic approach for the treatment of Non-alcoholic steatohepatitis." @default.
• W2891145791 created "2018-09-27" @default.
• W2891145791 creator A5007288259 @default.
• W2891145791 creator A5023784321 @default.
• W2891145791 creator A5034100206 @default.
• W2891145791 creator A5035086772 @default.
• W2891145791 creator A5039903946 @default.
• W2891145791 creator A5047958048 @default.
• W2891145791 creator A5058114124 @default.
• W2891145791 creator A5072053322 @default.
• W2891145791 creator A5077241319 @default.
• W2891145791 creator A5090797998 @default.
• W2891145791 date "2018-10-01" @default.
• W2891145791 modified "2023-10-18" @default.
• W2891145791 title "Therapeutic inhibition of spleen tyrosine kinase in inflammatory macrophages using PLGA nanoparticles for the treatment of non-alcoholic steatohepatitis" @default.
• W2891145791 cites W1903259758 @default.
• W2891145791 cites W1967206613 @default.
• W2891145791 cites W1982661637 @default.
• W2891145791 cites W1996644651 @default.
• W2891145791 cites W2000369852 @default.
• W2891145791 cites W2003110090 @default.
• W2891145791 cites W2017341404 @default.
• W2891145791 cites W2022790785 @default.
• W2891145791 cites W2023452119 @default.
• W2891145791 cites W2025355874 @default.
• W2891145791 cites W2049399201 @default.
• W2891145791 cites W2050207992 @default.
• W2891145791 cites W2053386771 @default.
• W2891145791 cites W2087032263 @default.
• W2891145791 cites W2087859983 @default.
• W2891145791 cites W2101935191 @default.
• W2891145791 cites W2124532149 @default.
• W2891145791 cites W2168181266 @default.
• W2891145791 cites W2211370063 @default.
• W2891145791 cites W2290278411 @default.
• W2891145791 cites W2341568598 @default.
• W2891145791 cites W2364200298 @default.
• W2891145791 cites W2375136717 @default.
• W2891145791 cites W2431369884 @default.
• W2891145791 cites W2472849417 @default.
• W2891145791 cites W2519860162 @default.
• W2891145791 cites W2552083010 @default.
• W2891145791 cites W2577902252 @default.
• W2891145791 cites W2594491387 @default.
• W2891145791 cites W2608418856 @default.
• W2891145791 cites W2740226484 @default.
• W2891145791 cites W2774934615 @default.
• W2891145791 cites W2789776190 @default.
• W2891145791 cites W2804456129 @default.
• W2891145791 cites W4255712601 @default.
• W2891145791 cites W43493097 @default.
• W2891145791 doi "https://doi.org/10.1016/j.jconrel.2018.09.004" @default.
• W2891145791 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30219279" @default.
• W2891145791 hasPublicationYear "2018" @default.
• W2891145791 type Work @default.
• W2891145791 sameAs 2891145791 @default.
• W2891145791 citedByCount "33" @default.
• W2891145791 countsByYear W28911457912019 @default.
• W2891145791 countsByYear W28911457912020 @default.
• W2891145791 countsByYear W28911457912021 @default.
• W2891145791 countsByYear W28911457912022 @default.
• W2891145791 countsByYear W28911457912023 @default.
• W2891145791 crossrefType "journal-article" @default.
• W2891145791 hasAuthorship W2891145791A5007288259 @default.
• W2891145791 hasAuthorship W2891145791A5023784321 @default.
• W2891145791 hasAuthorship W2891145791A5034100206 @default.
• W2891145791 hasAuthorship W2891145791A5035086772 @default.
• W2891145791 hasAuthorship W2891145791A5039903946 @default.
• W2891145791 hasAuthorship W2891145791A5047958048 @default.
• W2891145791 hasAuthorship W2891145791A5058114124 @default.
• W2891145791 hasAuthorship W2891145791A5072053322 @default.
• W2891145791 hasAuthorship W2891145791A5077241319 @default.
• W2891145791 hasAuthorship W2891145791A5090797998 @default.
• W2891145791 hasBestOaLocation W28911457911 @default.
• W2891145791 hasConcept C142724271 @default.
• W2891145791 hasConcept C185592680 @default.
• W2891145791 hasConcept C203014093 @default.
• W2891145791 hasConcept C2776914184 @default.
• W2891145791 hasConcept C2778772119 @default.
• W2891145791 hasConcept C2779134260 @default.
• W2891145791 hasConcept C2779478299 @default.
• W2891145791 hasConcept C35174551 @default.
• W2891145791 hasConcept C42362537 @default.
• W2891145791 hasConcept C502942594 @default.
• W2891145791 hasConcept C55493867 @default.
• W2891145791 hasConcept C62478195 @default.
• W2891145791 hasConcept C71924100 @default.
• W2891145791 hasConcept C98274493 @default.
• W2891145791 hasConceptScore W2891145791C142724271 @default.
• W2891145791 hasConceptScore W2891145791C185592680 @default.
• W2891145791 hasConceptScore W2891145791C203014093 @default.
• W2891145791 hasConceptScore W2891145791C2776914184 @default.
• W2891145791 hasConceptScore W2891145791C2778772119 @default.
• W2891145791 hasConceptScore W2891145791C2779134260 @default.
• W2891145791 hasConceptScore W2891145791C2779478299 @default.
• W2891145791 hasConceptScore W2891145791C35174551 @default.
• W2891145791 hasConceptScore W2891145791C42362537 @default.
• W2891145791 hasConceptScore W2891145791C502942594 @default.

• next